LifeStance Reports Third Quarter 2021 Results

Go back to LifeStance Reports Third Quarter 2021 Results

JPMorgan Downgrades Lifestance Health Group (LFST) to Neutral

November 9, 2021 6:59 AM EST

JPMorgan analyst Lisa Gill downgraded Lifestance Health Group (NASDAQ: LFST) from Overweight to Neutral with a price target of $12.00 (from $24.00).

The analyst comments "We are downgrading shares of LifeStance Health to Neutral from Overweight and lowering our Dec-22 price target to $12 from $24. LFST... More

LifeStance Health Group, Inc. (LFST) Misses Q3 EPS by 11c

November 8, 2021 4:39 PM EST

LifeStance Health Group, Inc. (NASDAQ: LFST) reported Q3 EPS of ($0.35), $0.11 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $173.8 million versus the consensus estimate of $171.36 million.

GUIDANCE:

LifeStance Health Group, Inc. sees FY2021 revenue of... More